SLC7A11 and osteosarcoma: Pharmacological inhibition of SLC7A11 with the FDA-approved anti-inflammatory drug sulfasalazine leads to ferroptosis and impairs the growth of xenografted osteosarcoma cells, highlighting the potential of targeting SLC7A11 in osteosarcoma treatment (Fig. 7).